Top Page
Yestar Healthcare Holdings Co Ltd
(2393)
Yestar Healthcare Holdings Co Ltd (2393) vs. iShares MSCI Hong Kong ETF (EWH)
Yestar Healthcare Holdings Co Ltd Business Overview & Revenue Model
Yestar Healthcare Holdings Co Ltd Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 2.41B | 2.91B | 4.29B | 4.93B | 4.11B |
| Gross Profit | ||||
| 399.20M | 512.78M | 708.71M | 848.70M | 806.88M |
| EBIT | ||||
| -153.66M | 143.59M | -77.51M | 184.37M | 158.14M |
| EBITDA | ||||
| -51.93M | 376.81M | 19.13M | 315.89M | -317.26M |
| Net Income Common Stockholders | ||||
| 921.61M | -13.89M | -992.23M | 3.33M | -590.49M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 151.78M | 251.56M | 418.15M | 751.77M | 687.13M |
| Total Assets | ||||
| 1.43B | 3.43B | 3.37B | 4.56B | 4.66B |
| Total Debt | ||||
| 316.90M | 1.63B | 1.90B | 1.79B | 1.84B |
| Net Debt | ||||
| 223.13M | 1.43B | 1.60B | 1.21B | 1.27B |
| Total Liabilities | ||||
| 921.84M | 3.82B | 3.71B | 3.73B | 3.80B |
| Stockholders Equity | ||||
| 461.60M | -457.50M | -408.87M | 755.23M | 757.04M |
| Cash Flow | Free Cash Flow | |||
| 0.00 | 294.22M | -115.58M | 665.55M | 591.92M |
| Operating Cash Flow | ||||
| 0.00 | 387.67M | -91.73M | 715.22M | 670.73M |
| Investing Cash Flow | ||||
| 0.00 | -89.82M | -18.72M | -47.67M | -37.21M |
| Financing Cash Flow | ||||
| 0.00 | -234.37M | -180.86M | -654.20M | -604.74M |
Yestar Healthcare Holdings Co Ltd Technical Analysis
Yestar Healthcare Holdings Co Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$27.41B | 12.27 | 8.95% | 4.46% | -3.09% | 0.67% | |
74 Outperform | $34.08B | 12.80 | 14.56% | 3.78% | -5.37% | 6.28% | |
66 Neutral | $98.90B | 52.12 | 6.14% | 2.17% | 7.63% | -24.23% | |
56 Neutral | HK$59.66B | 251.27 | 0.42% | 0.56% | -2.06% | -83.44% | |
54 Neutral | $5.37B | 3.26 | -45.10% | 3.30% | 16.81% | 0.02% | |
51 Neutral | HK$396.04M | 0.40 | 1417.08% | ― | -20.01% | ― | |
48 Neutral | HK$594.23M | ― | -10.78% | ― | -0.95% | -128.35% |
Yestar Healthcare Holdings Co Ltd Corporate Events
Yestar Healthcare Holdings Co Ltd has announced its Annual General Meeting scheduled for May 30, 2025, in Shanghai. The meeting will address several key agenda items, including the re-election of directors, the authorization of directors’ remuneration, and the re-appointment of auditors. Additionally, a resolution will be considered to allow the directors to issue additional shares, which could impact the company’s capital structure and shareholder value.
Yestar Healthcare Holdings Co Ltd has announced a change in its principal place of business in Shanghai, effective from April 15, 2025. This relocation to a new address in Pudong New District signifies a strategic move that could enhance operational efficiency and potentially strengthen its market position in the region.
Yestar Healthcare Holdings Co Ltd has announced key leadership changes effective April 2, 2025. Mr. Wang Chunlai has been appointed as an executive director, bringing extensive experience within the company since 2000. Concurrently, Ms. Liao Changxiang has resigned as CEO and member of the investment committee, transitioning to a general manager role for the Guangxi operations. These changes are part of a succession plan aimed at strengthening the company’s management structure and operational focus.
Yestar Healthcare Holdings Co Ltd has announced the composition of its board of directors and the roles within its various committees. This organizational update, effective immediately, includes the appointment of members to the Audit, Nomination, Remuneration, and Investment Committees, which could influence the company’s governance and strategic decisions.
Yestar Healthcare Holdings Co Ltd has announced the implementation of a succession plan for the role of chief executive officer as part of its strategy to diversify and strengthen its management team. This plan includes a rotating CEO management system aimed at promoting sustainable development, enhancing organizational efficiency, and fostering innovation within the company. The board believes this initiative will improve corporate governance and support the company’s long-term success, benefiting both the group and its shareholders.
Yestar Healthcare Holdings Co Ltd announced its annual results for the year ended December 31, 2024, reporting a significant increase in profit from continuing operations, reaching RMB 902,977,000 compared to RMB 1,478,000 in the previous year. This improvement is attributed to a substantial gain on the extinguishment of senior notes and a reduction in finance costs, despite a decrease in revenue and an impairment loss on non-financial assets. The results indicate a positive shift in the company’s financial health, potentially strengthening its market position and offering reassurance to stakeholders.
Yestar Healthcare Holdings Co Ltd has announced a board meeting scheduled for March 28, 2025, to discuss and approve the company’s annual results for the year ending December 31, 2024. The meeting will also consider the recommendation of a final dividend, highlighting the company’s ongoing financial strategies and potential returns for stakeholders.
Yestar Healthcare Holdings Co Ltd has announced a positive profit alert, expecting to report a consolidated net profit of at least RMB880 million for the fiscal year 2024, a significant turnaround from the previous year’s net loss of approximately RMB1.3 million. This improvement is attributed to gains from the redemption of senior notes, reduced finance costs, and a reversal of impairment loss on financial assets, although partially offset by increased impairment losses on other assets. The final audited results will be released on March 28, 2025.